行情

IMMP

IMMP

Immutep
NASDAQ

实时行情|Nasdaq Last Sale

2.810
+0.130
+4.85%
盘后: 2.800 -0.01 -0.36% 16:51 02/21 EST
开盘
2.690
昨收
2.680
最高
2.850
最低
2.680
成交量
19.72万
成交额
--
52周最高
3.230
52周最低
1.270
市值
1,020.48万
市盈率(TTM)
-0.7139
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测IMMP价格均价为5.41,最高价位6.88,最低价为3.934。

EPS

IMMP 新闻

更多
  • Immutep Reports Positive TACTI-002 Data
  • GlobeNewswire · 3天前
  • The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
  • Benzinga · 3天前
  • The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
  • Benzinga · 3天前
  • The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions
  • Benzinga · 5天前

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

IMMP 简况

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
展开

微牛提供Immutep Ltd(NASDAQ-IMMP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的IMMP股票新闻,以帮助您做出投资决策。